Affiliations 

  • 1 Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand
  • 2 PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Bandar Seri Begawan, Brunei Darussalam
  • 3 Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
  • 4 Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore
  • 5 Department of Pharmacy, College of Pharmacy, University of the Philippines, Manila, Philippines
  • 6 Department of Pharmaceutical Services, Ministry of Health, Bandar Seri Begawan, Brunei Darussalam
  • 7 Kathmandu Medical College Teaching Hospital, Kathmandu, Nepal
  • 8 Department of Biochemistry, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand
  • 9 Department of Oral Pathology, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand
  • 10 Center for Medical Genomics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
  • 11 School of Biotechnology, International University, Vietnam National University, Ho Chi Minh City, Vietnam
  • 12 Defence Services Medical Research Centre (DSMRC), Nay Pyi Taw, Myanmar/Burma
  • 13 Department of Medical Sciences, Medical Genetics Center, Medical Life Sciences Institute, Ministry of Public Health, Nonthaburi, Thailand
  • 14 School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia
  • 15 National Center for Laboratory and Epidemiology, Vientiane Capital, Laos
  • 16 Department of Pharmacology, Faculty of Medicine, YARSI University, Jakarta, Indonesia
  • 17 Department of Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 18 Center for Medical Genomics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, wasun.cha@mahidol.ac.th
Public Health Genomics, 2019;22(3-4):132-139.
PMID: 31587001 DOI: 10.1159/000502916

Abstract

Pharmacogenomics (PGx) is increasingly being recognized as a potential tool for improving the efficacy and safety of drug therapy. Therefore, several efforts have been undertaken globally to facilitate the implementation process of PGx into routine clinical practice. Part of these efforts include the formation of PGx working groups working on PGx research, synthesis, and dissemination of PGx data and creation of PGx implementation strategies. In Asia, the Southeast Asian Pharmacogenomics Research Network (SEAPharm) is established to enable and strengthen PGx research among the various PGx communities within but not limited to countries in SEA; with the ultimate goal to support PGx implementation in the region. From the perspective of SEAPharm member countries, there are several key elements essential for PGx implementation at the national level. They include pharmacovigilance database, PGx research, health economics research, dedicated laboratory to support PGx testing for both research and clinical use, structured PGx education, and supportive national health policy. The status of these essential elements is presented here to provide a broad picture of the readiness for PGx implementation among the SEAPharm member countries, and to strengthen the PGx research network and practice in this region.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.